Industry Briefing
A single destination for timely, editor-curated robotics news from around the world.
Travere Therapeutics Sees Surge in Sales Following FILSPARI Approval for FSGS
On April 13, 2026, the FDA granted Travere Therapeutics full approval for FILSPARI, a treatment for focal segmental glomerulosclerosis (FSGS). This marked the drug's second full approval, following a previous clearance for IgA nephropathy in 2023. The approval is significant for patients aged 8 and older with specific subtypes of FSGS, as it offers a new FDA-approved option for a previously underserved condition. The approval is crucial as FSGS can lead to kidney failure, and patients have historically relied on off-label therapies. Travere's Chief Executive Eric Dube emphasized the milestone for FSGS patients, while industry leaders noted the life-changing potential of the drug. Following the approval, Travere reported substantial sales growth, with FILSPARI's U.S. net product sales reaching $105.2 million in Q1 2026, an 88% increase from the previous year, and $141.1 million in Q2 2026, a 96% year-over-year rise. Looking ahead, Travere's first-half 2026 sales totaled $246.2 million, indicating strong market demand for FILSPARI. The company also reported its first quarter of non-GAAP profitability. No further timeline was disclosed at the time of publication.
Business Financials & Investments armistice capital biotech investing biotech stocks civorebrutinibRobotics needs a service framework.
RSF defines a common language for robot service capability, lifecycle operations, certification pathways, and service-provider networks.
Join the RobotToday community on LinkedIn
Daily robotics news, in-depth analysis, conference highlights, and discussions with professionals worldwide.
